Physician profile
Debra L Wolf
NPI 1508155417
$1,863.72
in general payments reported to CMS, 2019-2025
20 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $498 · 2023: $422 · 2024: $417 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $457.98 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $396.66 | 2021-2024 | |
| Novo Nordisk INC | $183.90 | 2021-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $106.92 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $105.82 | 2022-2025 | |
| Lilly USA, LLC | $99.65 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $98.53 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.09 | 2021-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.27 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $60.97 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $35.40 | 2021-2023 | Verquvo, Steglujan, Segluromet |
| Biohaven Pharmaceuticals, INC. | $25.88 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.97 | 2022 | |
| Axsome Therapeutics, INC. | $23.58 | 2024 | Auvelity |
| Dexcom, INC. | $19.64 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.37 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $19.05 | 2024 | Voquezna |
| Pulmonx Corporation | $16.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.74 | 2021 | |
| Amgen INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.